Circassia Pharmaceuticals (CIR) Earns Buy Rating from Numis Securities
Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reiterated by stock analysts at Numis Securities in a research report issued on Monday. They currently have a GBX 180 ($2.41) price objective on the biopharmaceutical company’s stock. Numis Securities’ price target indicates a potential upside of 68.22% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Peel Hunt reaffirmed a “hold” rating and set a GBX 130 ($1.74) price target on shares of Circassia Pharmaceuticals in a research report on Wednesday, September 27th. J P Morgan Chase & Co dropped their price target on Circassia Pharmaceuticals from GBX 120 ($1.61) to GBX 110 ($1.47) and set a “neutral” rating on the stock in a research report on Thursday, September 28th.
Shares of Circassia Pharmaceuticals (LON:CIR) opened at GBX 107 ($1.43) on Monday. Circassia Pharmaceuticals has a 1 year low of GBX 76.75 ($1.03) and a 1 year high of GBX 114 ($1.53).
Circassia Pharmaceuticals Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.